Why do biotech investors ask about freedom to operate so early in due diligence?

Because an unresolved FTO issue is a potential veto on the entire investment thesis, not a minor risk to manage later. Investors are underwriting the probability that an asset will reach a specific exit at a specific valuation within a specific timeline. A blocking patent in a key market, a required licence held by a competitor, or a contested platform technology patent can each eliminate the commercial value of the asset or reprice the deal significantly. Discovering it during final due diligence, or after a term sheet has been signed, is considerably more damaging than addressing it beforehand.

Do I need a formal FTO opinion before approaching biotech investors?

For early conversations with seed-stage or angel investors, a formal opinion is typically not required, but evidence that the question has been considered is. A founder who can describe the relevant patent landscape, identify the potentially relevant third-party patents, and articulate a view on each one is in a much stronger position than one who has not engaged with the question. For a Series A institutional round or a pharma business development conversation, a formal FTO opinion from qualified IP counsel is expected. It needs to demonstrate that the risks are known, characterised, and addressed, or that there is a funded plan to address them.

What is the difference between freedom to operate and owning a patent?

A patent gives its owner the right to exclude others from using the patented invention. Freedom to operate addresses the separate question of whether your product or process infringes someone else's patents. The two are independent. A company can have a strong patent portfolio on its own inventions and still lack freedom to operate if a competitor holds patents on enabling technologies, manufacturing processes, or components required for commercialisation. In early-stage biotech, both questions matter, but FTO is the one that more frequently surprises founders during investor due diligence because it requires mapping the third-party landscape rather than simply documenting what the company owns.

How does freedom to operate affect biotech licensing and out-licensing deals?

In an out-licensing conversation, the potential licensee will conduct their own FTO analysis as part of due diligence. A clean FTO position, or a well-documented risk management plan for identified issues, accelerates the process and improves deal terms. An FTO problem discovered by the licensee during their own review creates negotiating leverage for the licensee and pressure on the licensor that almost always affects the deal economics. For academic TTOs, FTO issues discovered after a licensing term sheet has been agreed are particularly costly because they require renegotiation from a weakened position.

venture building

investor readiness

What is freedom to operate in biotech and why investors ask about it first

Q: What is freedom to operate in biotech?

Freedom to operate, or FTO, is the determination of whether a specific product, process, or technology can be developed, manufactured, and sold in a target market without infringing the valid intellectual property rights of a third party. It is distinct from owning IP: a company may hold strong patents on its own invention and still lack freedom to operate if a third party holds relevant patents on components, methods, or processes required for commercialisation. FTO is not binary. The result of a rigorous assessment is a risk profile covering which third-party patents are potentially relevant, how strong they are, and what options exist to manage each identified risk.

Freedom to operate is not a legal formality. It is a commercial signal. Here is what it means, why investors raise it early in due diligence, and what founders need to understand before the first investor meeting.

April 29, 2026

12 min read

Freedom to operate is one of the first questions a serious investor or pharma business development team will raise, and one of the last questions most early-stage founders have a prepared answer to. It is not a legal formality. It is a commercial signal: whether the company can develop, manufacture, and sell its product without infringing the valid intellectual property rights of a third party. An asset without a clear FTO position is not fundable, regardless of the quality of the science.

What freedom to operate actually means

Freedom to operate, commonly referred to as FTO, is the determination of whether a specific product, process, or technology can be commercialised without infringing patents held by third parties. It is distinct from the question of whether you own IP: you may have a strong patent on your invention and still lack the freedom to operate if a third party holds a patent on a component, method, or process required to develop or manufacture it.

The practical scope of an FTO assessment covers the relevant markets where the product will be developed, manufactured, or sold. A patent landscape that is clear in the United States may have a different profile in Europe, Japan, or other key markets. For a European biotech startup planning a pharma exit, the FTO position in the markets where the likely acquirer operates is the relevant scope, not just the domestic position.

FTO is not binary. The outcome of a rigorous assessment is rarely a simple yes or no. It is a risk profile: which third-party patents are potentially relevant, how strong they are, when they expire, whether they are being enforced, and what options exist to manage any risk identified. Those options typically include designing around problematic patents, seeking a licence from the patent holder, challenging the validity of the relevant patent, or accepting a calculated risk that the patent will not be enforced in the relevant context. Each of these is a commercial and legal decision that requires specialist IP counsel.

Having a strong patent on your own invention is not the same as having freedom to operate. The two questions are related but not the same, and investors know the difference.

Why investors raise it early in due diligence

The reason FTO appears early in the investor due diligence process, often in the first substantive conversation rather than in the legal review phase, is structural. An investor evaluating an early-stage biotech asset is underwriting a probability: the probability that this asset will reach the exit they are planning for, at the valuation they need, within the timeline their fund requires. An unresolved FTO issue is not a minor risk to be managed later. It is a potential veto on the entire investment thesis.

A third-party patent that blocks the manufacture or sale of the product in a key market can eliminate the commercial value of the asset entirely. A patent that requires licensing from a competitor changes the economics of the exit. A contested patent landscape that requires years of litigation introduces timeline and cost uncertainty that reprices the deal. None of these outcomes is acceptable to an institutional investor who has modelled the return on a specific set of assumptions about what the asset can generate.

The specific scenarios that generate the most concern during due diligence:

Blocking patents held by a direct competitor

A patent held by a company that would be a direct commercial rival, or that is developing an asset in the same space, creates both a legal risk and a strategic signal that the space is contested in ways the founder may not have fully mapped.

Platform technology patents

Early biotech assets often rely on platform technologies developed by others. CRISPR is the canonical example: patents covering fundamental CRISPR-Cas9 editing methods have generated disputes that touch multiple companies building on the platform. An asset that depends on a third-party platform needs a clear licence or a documented design-around.

Expired but recently filed divisionals

A core patent may have expired, but divisional applications covering narrower aspects of the technology may still be pending or recently issued. Founders who have checked the expiry date of the main patent but not investigated the divisional landscape are presenting an incomplete picture.

Undocumented licences

In academic spinouts, the IP may have been developed using tools, materials, or methods that were licensed from third parties under agreements that restrict commercial use. Those restrictions may not be visible in the patent landscape but are equally limiting.

What founders need to prepare before the first investor meeting

The question founders most frequently ask about FTO is whether they need a full formal analysis before approaching investors. The answer depends on the stage of the asset and the sophistication of the investors being approached.

Seed and early-stage conversations

A formal FTO opinion is typically not necessary. What is necessary is evidence that the question has been asked. A founder who can credibly describe the relevant patent landscape, identify the potentially relevant third-party patents, and articulate a view on how each one affects the commercialisation path is in a materially stronger position than one who has not engaged with the question at all.

Series A and pharma BD engagements

A formal FTO opinion prepared by qualified IP counsel is expected. It does not need to be perfect, and no experienced investor expects a risk-free landscape. What they expect is that the risk has been identified, characterised, and addressed, or that there is a documented plan to address it with the current round of capital.

The most damaging position is not having an unfavourable FTO profile. It is having an unfavourable FTO profile that the founding team was not aware of when the investor asked. Discovery of an unacknowledged IP risk during due diligence is not just a legal problem. It is a credibility problem that affects the entire investment relationship.

An unfavourable FTO profile does not necessarily kill a deal. An unfavourable FTO profile the founding team did not know about almost always does.

The FTO question for academic spinouts and TTOs

For principal investigators and technology transfer offices, the FTO question has an additional layer of complexity. Academic research is frequently conducted using tools, reagents, biological materials, and methods that are covered by third-party patents and licensed under agreements that permit research use but restrict commercial application.

The transition from a research context, where use of a patented tool is permitted under a research licence or implied licence, to a commercial context, where the same use may require a separate commercial licence, is a point where many academic spinouts discover a constraint they did not anticipate. The IP due diligence that a TTO conducts for the purposes of filing a patent on the spinout's invention is not the same as an FTO analysis for commercial development. The two cover different questions.

A university may hold strong patents on the core invention and have conducted a thorough IP review of what it owns. The FTO analysis asks what it is free to use, which is a broader and sometimes more difficult question. For TTOs preparing assets for licensing conversations with pharma or for spinout formation, commissioning a preliminary FTO landscape review before approaching commercial partners is almost always worth the investment. It either confirms the position or identifies issues that are cheaper to resolve before a partner is engaged than during the negotiation.

Like what you're reading?

Subscribe for more strategic notes on biotech and venture design.

Frequently asked questions

FTO is not the most exciting part of building a fundable biotech asset. It is the part that investors check before anything else, and the part most founders prepare last.

Book a 30-minute call